AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Massachusetts

H2203

Establishing a pilot program for access to regulated psilocybin

Status

Pending

2026 Session

IntroducedFeb 27, 2025 (done)
PassedNext step (current)
Signed— (upcoming)
Law in effect— (upcoming)

Sponsor: Marjorie Decker (Democrat)
Type: Therapeutic Access
Substances: Psilocybin

Official text

Summary (from PoliPsy)

For legislation to authorize the Department of Public Health to establish a pilot program for psilocybin services for adults with post-traumatic stress disorder and other specified conditions. Mental Health, Substance Use and Recovery.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: malegislature.gov

Legislative history

July 22, 2026
Referred
July 22, 2026
Referred
March 23, 2026
Referred
February 27, 2025
Referred
February 27, 2025
Introduced

Loading bill…